iBio (IBIO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

IBIO · Stock Price

USD 1.64-0.45 (-21.53%)

Market Cap: $59.3M

Historical price data

Overview

iBio's mission is to develop next-generation antibody therapies for obesity and cardiometabolic disorders, targeting validated but historically difficult-to-drug pathways like GPCRs. Its core achievement is the creation of an integrated AI and wet-lab discovery platform designed to accelerate development and reduce late-stage failure risks. The company's strategy focuses on advancing a pipeline of fully human antibodies with improved profiles—such as muscle preservation and less frequent dosing—through clinical validation, while exploring strategic partnerships to expand its impact.

ObesityCardiometabolic Disease

Technology Platform

An integrated AI and wet-lab platform combining Epitope-Steering computational antigen design, Mammalian Display for function-first selection, and StableHu™ AI-optimized antibody libraries to discover fully human antibodies against difficult targets like GPCRs.

Pipeline

3

3 drugs in pipeline

Drug	Indication	Stage
PHI-101 administration	Platinum-resistant Ovarian Cancer	Phase 1
IBIO-600 + Placebo	Overweight , Obesity	Phase 1
PHI-101	Relapsed or Refractory Acute Myeloid Leukemia	Phase 1

Opportunities

iBio is positioned to capitalize on the massive, growing obesity therapeutics market by addressing key limitations of current GLP-1 drugs, such as muscle loss and frequent dosing.

Its AI platform could enable rapid discovery of best-in-class, tissue-selective antibodies, creating opportunities for high-value partnerships and pipeline expansion into other disease areas with difficult-to-drug targets.

Risk Factors

The company faces high clinical development risk with its pre-clinical pipeline, significant financial risk as a pre-revenue entity with a low market cap, and intense competition from large pharma and other biotechs in the fast-moving obesity space.

Failure to validate its AI platform in human trials would fundamentally impair its value proposition.

Competitive Landscape

iBio competes in the obesity space against dominant peptide developers (Novo Nordisk, Eli Lilly) and a growing field of biotechs. Its primary differentiation is its antibody modality focused on muscle preservation and its AI platform targeting GPCRs. Success likely depends on positioning its candidates as complementary, rather than directly competitive, to established GLP-1 therapies.

More companies in AI / Machine Learning →More companies in United States →